6 citations
,
August 2023 in “Fertility and Sterility” This review details the 2023 International Guideline update for assessing and managing polycystic ovary syndrome, which provides evidence-based recommendations to improve care and patient outcomes but notes the remaining low to moderate quality of evidence.
63 citations
,
August 2022 in “Diagnostics” This review discusses hirsutism in women with PCOS who present with normal androgen levels and highlights diagnostic challenges, reporting no new clinical findings.
14 citations
,
March 2022 in “Clinical Endocrinology” This review outlines a diagnostic approach for identifying non-PCOS pathology in women with androgen excess, emphasizing the importance of clinical history and biochemical phenotyping but reports no new clinical results.
8 citations
,
August 2020 in “Clinical and Experimental Dermatology” In this review, spironolactone is highlighted for its emerging use in dermatology, particularly for treating androgen-mediated conditions like acne and hirsutism in susceptible females, though it requires careful monitoring for potential adverse effects.
28 citations
,
January 2017 in “Indian Dermatology Online Journal” In this study, skin manifestations such as hirsutism and acne were prevalent among women with PCOS, highlighting their importance in diagnosis and symptomatology.
1540 citations
,
October 2008 in “Fertility and Sterility” This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.
4025 citations
,
December 2003 in “Human Reproduction” This review discusses the evolution of diagnostic criteria for polycystic ovary syndrome and emphasizes its association with various metabolic and cardiovascular risks, but it provides no new research findings.
78 citations
,
January 2000 in “Gynecological Endocrinology” This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.